Brought to you by 
Isis, equity firm create Altair, license respiratory assets
31 Oct 2007
Executive Summary
Private equity firm Thomas, McNerney & Partners and Isis Pharmaceuticals have launched the new company Altair Therapeutics to focus on Isis' antisense respiratory candidates. Isis, which owns 18% of the start-up, simultaneously gave Altair exclusive global rights to develop and sell its ISIS369645 for asthma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Isis, equity firm create Altair, license respiratory assets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice